Differential Regulation of Amyloid-β Endocytic Trafficking and Lysosomal Degradation by Apolipoprotein E Isoforms*♦

Background: Apolipoprotein E (apoE) regulates amyloid-β (Aβ) clearance in an isoform-dependent manner. Results: Internalized Aβ traffics to lysosomal and recycling pathways. ApoE3 more efficiently promotes Aβ lysosomal trafficking and degradation than apoE4. Conclusion: ApoE isoforms differentially affect Aβ lysosomal trafficking and degradation. Significance: Differential effects of apoE isoforms on Aβ cellular degradation may explain why apoE4 is a risk factor for Alzheimer disease. Aggregation of amyloid-β (Aβ) peptides leads to synaptic disruption and neurodegeneration in Alzheimer disease (AD). A major Aβ clearance pathway in the brain is cellular uptake and degradation. However, how Aβ traffics through the endocytic pathway and how AD risk factors regulate this event is unclear. Here we show that the majority of endocytosed Aβ in neurons traffics through early and late endosomes to the lysosomes for degradation. Overexpression of Rab5 or Rab7, small GTPases that function in vesicle fusion for early and late endosomes, respectively, significantly accelerates Aβ endocytic trafficking to the lysosomes. We also found that a portion of endocytosed Aβ traffics through Rab11-positive recycling vesicles. A blockage of this Aβ recycling pathway with a constitutively active Rab11 mutant significantly accelerates cellular Aβ accumulation. Inhibition of lysosomal enzymes results in Aβ accumulation and aggregation. Importantly, apolipoprotein E (apoE) accelerates neuronal Aβ uptake, lysosomal trafficking, and degradation in an isoform-dependent manner with apoE3 more efficiently facilitating Aβ trafficking and degradation than apoE4, a risk factor for AD. Taken together, our results demonstrate that Aβ endocytic trafficking to lysosomes for degradation is a major Aβ clearance pathway that is differentially regulated by apoE isoforms. A disturbance of this pathway can lead to accumulation and aggregation of cellular Aβ capable of causing neurotoxicity and seeding amyloid.

[1]  Thomas W. Mühleisen,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2013, Nature Genetics.

[2]  L. Mucke,et al.  Alzheimer Mechanisms and Therapeutic Strategies , 2012, Cell.

[3]  D. Holtzman,et al.  Low-density Lipoprotein Receptor Represents an Apolipoprotein E-independent Pathway of Aβ Uptake and Degradation by Astrocytes* , 2012, The Journal of Biological Chemistry.

[4]  Guojun Bu,et al.  Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[5]  B. Strooper,et al.  The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes , 2012, Nature Neuroscience.

[6]  A. Fagan,et al.  Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance , 2011, Science Translational Medicine.

[7]  D. G. Clark,et al.  Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease , 2011, Nature Genetics.

[8]  G. Bu,et al.  Heparan Sulphate Proteoglycan and the Low-Density Lipoprotein Receptor-Related Protein 1 Constitute Major Pathways for Neuronal Amyloid-β Uptake , 2011, The Journal of Neuroscience.

[9]  R. Bateman,et al.  Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.

[10]  G. Bu,et al.  Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) Mediates Neuronal Aβ42 Uptake and Lysosomal Trafficking , 2010, PloS one.

[11]  Du Feng,et al.  Membrane localization of beta-amyloid 1-42 in lysosomes: a possible mechanism for lysosome labilization. , 2010, The Journal of biological chemistry.

[12]  D. Westaway,et al.  Lysosomal Proteolysis and Autophagy Require Presenilin 1 and Are Disrupted by Alzheimer-Related PS1 Mutations , 2010, Cell.

[13]  D. Dickson,et al.  IFN-γ Promotes Complement Expression and Attenuates Amyloid Plaque Deposition in Amyloid β Precursor Protein Transgenic Mice , 2010, The Journal of Immunology.

[14]  M. Gobbi,et al.  Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein , 2010, Proceedings of the National Academy of Sciences.

[15]  Jin-Moo Lee,et al.  Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide , 2009, Proceedings of the National Academy of Sciences.

[16]  T. Sata,et al.  HIV-1 Accessory Protein Vpu Internalizes Cell-surface BST-2/Tetherin through Transmembrane Interactions Leading to Lysosomes* , 2009, The Journal of Biological Chemistry.

[17]  L. Kiemeney,et al.  Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.

[18]  H. Stenmark Rab GTPases as coordinators of vesicle traffic , 2009, Nature Reviews Molecular Cell Biology.

[19]  Sirkka Goebeler,et al.  Apolipoprotein E–dependent accumulation of Alzheimer disease–related lesions begins in middle age , 2009, Annals of neurology.

[20]  Guojun Bu,et al.  Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy , 2009, Nature Reviews Neuroscience.

[21]  D. Holtzman,et al.  Microglia Mediate the Clearance of Soluble Aβ through Fluid Phase Macropinocytosis , 2009, The Journal of Neuroscience.

[22]  Ralph A. Nixon,et al.  Autophagy Induction and Autophagosome Clearance in Neurons: Relationship to Autophagic Pathology in Alzheimer's Disease , 2008, The Journal of Neuroscience.

[23]  A. Gräslund,et al.  Time-resolved infrared spectroscopy of pH-induced aggregation of the Alzheimer Abeta(1-28) peptide. , 2008, Journal of molecular biology.

[24]  Ralph A. Nixon,et al.  Autophagy, amyloidogenesis and Alzheimer disease , 2007, Journal of Cell Science.

[25]  M. Goedert,et al.  A Century of Alzheimer's Disease , 2006, Science.

[26]  C. Finch,et al.  Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers , 2004, The Journal of Neuroscience.

[27]  J. Buxbaum,et al.  Aβ localization in abnormal endosomes: association with earliest Aβ elevations in AD and Down syndrome , 2004, Neurobiology of Aging.

[28]  V. Puri,et al.  Rab proteins mediate Golgi transport of caveola-internalized glycosphingolipids and correct lipid trafficking in Niemann-Pick C cells. , 2002, The Journal of clinical investigation.

[29]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[30]  A. Yang,et al.  Lysosomal Membrane Damage in Soluble Aβ-Mediated Cell Death in Alzheimer's Disease , 2001, Neurobiology of Disease.

[31]  B T Hyman,et al.  Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. , 2000, The American journal of pathology.

[32]  A. Yang,et al.  Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Aβ1‐42 pathogenesis , 1998, Journal of neuroscience research.

[33]  R. Nixon,et al.  Increased Neuronal Endocytosis and Protease Delivery to Early Endosomes in Sporadic Alzheimer’s Disease: Neuropathologic Evidence for a Mechanism of Increased β-Amyloidogenesis , 1997, The Journal of Neuroscience.

[34]  K Kontula,et al.  Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. , 1995, The New England journal of medicine.

[35]  G. Getz,et al.  Purification of Apolipoprotein E Attenuates Isoform-specific Binding to -Amyloid (*) , 1995, The Journal of Biological Chemistry.

[36]  G. Getz,et al.  Isoform-specific binding of apolipoprotein E to beta-amyloid. , 1994, The Journal of biological chemistry.

[37]  A D Roses,et al.  Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[38]  C. Glabe,et al.  Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/beta protein. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[39]  D. G. Clark,et al.  Common variants at MS 4 A 4 / MS 4 A 6 E , CD 2 AP , CD 33 and EPHA 1 are associated with late-onset Alzheimer ’ s disease , 2011 .

[40]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[41]  Nick C Fox,et al.  Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .

[42]  L. J. Eldik,et al.  ApoE and Aβ1–42 interactions , 2007, Journal of Molecular Neuroscience.

[43]  R. Nixon,et al.  Lysosomal system pathways: genes to neurodegeneration in Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.

[44]  D. Selkoe,et al.  Natural oligomers of the amyloid-β protein specifically disrupt cognitive function , 2005, Nature Neuroscience.

[45]  L. V. Van Eldik,et al.  ApoE and Abeta1-42 interactions: effects of isoform and conformation on structure and function. , 2004, Journal of molecular neuroscience : MN.

[46]  P. Mathews,et al.  The neuronal endosomal-lysosomal system in Alzheimer's disease. , 2001, Journal of Alzheimer's disease : JAD.

[47]  Donald,et al.  Isoform-specific Binding of Apolipoprotein E to p-Amyloid* , 2001 .

[48]  R. Mahley,et al.  Apolipoprotein E: far more than a lipid transport protein. , 2000, Annual review of genomics and human genetics.